Item 2.02 Results of Operations and Financial Condition. On February 25, 2026, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583. The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
IONS Ionis Pharmaceuticals Inc - 8-K
Accession
0001140361-26-0067182.029.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 9.01 - Financial Statements and Exhibits
30 words
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated February 25, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).